Cerus Co. (CERS) Given Consensus Rating of “Hold” by Brokerages
Shares of Cerus Co. (NASDAQ:CERS) have earned an average rating of “Hold” from the eight ratings firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $6.40.
Several analysts have recently commented on CERS shares. ValuEngine lowered Cerus from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Robert W. Baird reissued a “buy” rating and issued a $5.00 target price on shares of Cerus in a research report on Friday, December 1st. Cowen set a $6.00 target price on Cerus and gave the company a “buy” rating in a research report on Thursday, October 5th. Zacks Investment Research raised Cerus from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research report on Wednesday, November 8th. Finally, BTIG Research reissued a “neutral” rating on shares of Cerus in a research report on Friday, December 8th.
Shares of Cerus (NASDAQ CERS) remained flat at $$3.64 on Monday. 886,300 shares of the company’s stock traded hands, compared to its average volume of 962,120. Cerus has a 1-year low of $1.93 and a 1-year high of $4.70. The company has a debt-to-equity ratio of 0.80, a quick ratio of 3.11 and a current ratio of 3.71. The stock has a market cap of $415.27, a PE ratio of -6.17 and a beta of 1.93.
Cerus (NASDAQ:CERS) last issued its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.03. Cerus had a negative return on equity of 142.18% and a negative net margin of 159.35%. The firm had revenue of $10.80 million during the quarter, compared to analyst estimates of $11.95 million. During the same quarter in the prior year, the business posted ($0.14) EPS. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. equities research analysts forecast that Cerus will post -0.59 earnings per share for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BB&T Securities LLC acquired a new position in shares of Cerus in the 3rd quarter valued at $100,000. UBS Asset Management Americas Inc. grew its position in Cerus by 59.3% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 48,377 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 18,000 shares during the period. Voya Investment Management LLC grew its position in Cerus by 22.0% during the 2nd quarter. Voya Investment Management LLC now owns 58,633 shares of the biotechnology company’s stock worth $147,000 after purchasing an additional 10,570 shares during the period. Turner Investments LLC acquired a new stake in Cerus during the 3rd quarter worth about $177,000. Finally, Ardsley Advisory Partners acquired a new stake in Cerus during the 2nd quarter worth about $200,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.